We performed a comprehensive evaluation of the pan-cancer potential of NCAPG as a predictive biomarker and identified its significant value in STAD, which may have implications for immunotherapy and is expected to provide a useful assessment system for clinical application. This evidence concerns the gene NCAPG and cancer.